Background: As splenectomy and spleen-preserving lymphadenectomy are performed only in some proximal gastric cancer patients, it is difficult to identify patients who have undergone radical gastrectomy with or without splenic hilar (No.10) Conclusions: Splenic hilar or splenic artery lymph node dissection was not associated with increased survival, in proximal gastric cancer patients without direct cancer invasion of the spleen and pancreas, regardless of whether splenectomy, pancreaticosplenectomy, or spleen-preserving lymphadenectomy was performed.
Background
Gastric cancer is a significant public health problem worldwide because it causes considerable morbidity and mortality [1] . Although the incidence of gastric cancer has decreased overall, that of proximal gastric cancer (PGC) has increased over the last few decades [2, 3] . PGC is a tumor located within the proximal third of the stomach, which includes the gastric cardia, esophagealgastric junction, and fundus. Compared to distal gastric cancers, PGCs have worse prognoses because they are more aggressive and tend to be advanced by the time of diagnosis [4, 5] .
Resection of the primary lesion with dissection of the D2 lymph nodes (LNs) is the only effective treatment for PGC. It is common to resect the spleen and/or the tail of the pancreas when gastrectomy is performed to completely remove the splenic hilar (No.10) and splenic artery (No.11) LNs. Because many studies have shown that splenectomy or pancreaticosplenectomy has higher postoperative complications and may not improve long-term survival, some researchers favor spleen-preserving lymphadenectomy for advanced proximal gastric cancer (APGC) [6] [7] [8] [9] . Although controversy exists regarding the approach of No.10 and No.11 lymphadenectomy, there is no doubt that patients with splenic hilar or splenic artery LN metastases (SLNMs) have very poor prognoses [10, 11] . Given the high rates of operative complications during No.10 and No.11 LN dissections involving splenectomy or pancreaticosplenectomy, and the difficulties and non-completion rates associated with No. 10 and No.11 LN dissections with spleen preservation, No.10 and No.11 LN dissections are not performed on all APGC patients. It is unclear whether APGC patients have increased survival rates after splenic hilar or splenic artery lymphadenectomy due to the difficulties in predicting SLNM preoperatively or intraoperatively.
The aim of this study was to determine the risk factors associated with SLNM by evaluating the clinicopathological characteristics relevant to SLNM in APGC patients who underwent curative gastrectomy with splenectomy, pancreaticosplenectomy, or spleen-preserving lymphadenectomy, and to clarify the prognostic significance of splenic hilar or splenic artery lymph node dissection in all patients with APCG.
Methods

Patients
Between January 1980 and October 2012, 1424 consecutive patients were histologically diagnosed with APGC and underwent radical proximal or total gastrectomy with D1 + /D2 lymphadenectomyat the First Affiliated Hospital of China Medical University. The exclusion criteria were as follows: (1) patients with early gastric cancer, distant metastases, peritoneal dissemination, and direct invasion of the spleen or pancreas; (2) patients who died of postoperative complications or non-tumorrelated events within 5 years of surgery; (3)patients who underwent chemotherapy or radiotherapy preoperatively; (4) patients with carcinomas in the remnant stomach; and (5) patients who were lost to follow-up. Consequently, 837 patients were included in the final analyses. In this study, the pathological tumor stage was evaluated using the 8th edition of the TNM-Union for International Cancer Control/AJCC classification.
Surgical approach and postoperative adjuvant therapy
During the early 1980s, we performed standard D2 lymphadenectomy and removed the spleen and distal pancreas. However, given the high operative mortality and morbidity rates, after the mid-1980s, we preserved the spleen and pancreas when possible, except in cases when the tumor directly invaded the spleen or pancreas, the tumor was > 5 cm in the greater curvature, or the tumor had invaded the serosa and measured > 10 cm. When swollen LNs were present near the splenic hilum or splenic artery, combined resections of the spleen and pancreas or spleen-preserving lymphadenectomy were considered.
Therefore Postoperative chemotherapy regimens included 5-fluorouracil (5-Fu) plus cisplatin, 5-Fu plus mitomycin and epirubicin, 5-Fuplusleucovorin and cisplatin, 5-Fu plus cisplatin and epirubicin, or cisplatin plus oxaliplatin.
Follow-up
All patients underwent standardized follow-up assessments every 3 months for the first 2 years postoperatively, every 6 months during the third postoperative year, and yearly thereafter. The follow-up interval spanned from the time of surgery until the patient's death or for 5-10 years after surgery. Patients who lived for > 5 years or died of non-cancer-related events were considered to have survived.
Statistical analysis
The chi-squared test was used to compare categorical variables. The Kaplan-Meier method was used for univariate survival analysis, and survival data were compared using the log-rank test. Multivariate analyses were performed using Cox proportional hazards models. All statistical analyses were conducted using IBM® SPSS® software version 22.0 (IBM Corporation, Armonk, NY, USA). A two-sided value of P < 0.05 was considered statistically significant.
Results
Patients' characteristics and types of surgery
Of the APGC patients analyzed, 502 (60.0%) underwent total gastrectomy and 335 (40.0%) underwent proximal gastrectomy. Of these, 152 patients (18.2%) were in the CR group, 113 patients (16.5%) were in the SPR group, and 572 patients (83.5%) were in the NSR group. As shown in (Fig. 1a-c) . Similarly, in the SPR group, patients who had No.10 + /11 + LNs had worse prognoses than those who hadNo.10
− LNs (5-year survival rates: 8.1 vs. 50.0%, P < 0.001) (Fig. 1d-f Table 2) .
Relationships between No.10/11 LN metastases and the clinicopathological factors of patients who underwent CR of the spleen and pancreas
As shown in Table 3 , No.10 + /11 + LNs were closely associated with metastases of No.1/3(P = 0.002), No.2/4(P < 0.001), No.6(P = 0.034), No.7(P < 0.001), No.8(P = 0.006), and No.9(P < 0.001) LNs, poorly differentiated tumors(P = 0.016), and tumor invasions of the greater curvature of the stomach (P < 0.001). Logistic regression analyses determined that No.2/4 LN metastases(P = 0.030) and tumor invasion of the greater curvature(P < 0.001) were independent risk factors for SLNM (Table 3) .
Consequently, we made a risk classification of SLNM. Of the 572 patients in the NSR group, 53 (9.3%) had a high level of risk for SLNM and 519 (90.7%) had a low to midlevel risk for SLNM. In the NSR group, females and patients with higher pathological tumor-node-metastasis (pTNM) stages were at a higher risk of SLNM (Table 4) . Patients with high SLNM risk had worse prognoses than those who had low to midlevel risk (5-year survival rates: 15.1 vs. 42.9%, P < 0.001), especially in pT3 (5-year survival rates: 25.0 vs. 49.9%, P < 0.001)and pT4a patients (5-year survival rates: 11.1 vs. 29.1%, P < 0.001) (Fig. 2) .
Prognostic impact of the lymphadenectomy approach on patients with No.10/11 LN metastases As shown in Fig. 3a , no significant differences in survival existed between the NSR group with high risk of SLNM and No.10 + /11 + LN patients of the CR or SPR groups (P = 0.242). Thus, regardless of whether spleen-preserving surgery was performed, lymphadenectomy approach did not affect the prognoses of patients with No.10 + /11 + LNs. Considering patients' distribution, no significant bias existed from pTNM stages (P = 0.473) (Fig. 3b) . In addition, for the patients with low to midlevel risk of SLNM, there was no difference in survival between the NSR, CR, and SPR groups in the same TNM stage (Fig. 4) . Operative features and postoperative complications in the NSR, CR, and SPR groups
The patients with NSR and SPR had a shorter operation time, lower incidence of perioperative transfusion, shorter hospital stay, and lower incidence of non-lethal surgical complication than patients within the CR group (Table 5) .
Discussion
The In this study, we explored the risk factors of SLNM in the CR and SPR groups and distinguished high-risk SLNM patients from NSR patients. Since spleen-preserving No.10/11 lymphadenectomies may leave residues, we analyzed the characteristics of 152 APGC patients who underwent CR and determined that No.2/4 LN metastases and tumor invasion of the greater curvature were independent risk factors for SLNM. This result is similar to that of previous studies [14, 15] . Moreover, they suggested the existence of an important lymphatic pathway from a primary tumor located in the greater curvature of the stomach to the No.10 or No.11 LNs via the posterior gastric artery, short gastric vessels, or gastroepiploic vessels. This corresponded to observations from a study that used carbon particles to map lymphatic flow in PGC patients [16] . We defined patients with No.2/4 LN metastases and tumor invasion of the greater curvature as being at high risk of SLNMs and verified the reliability of these risk factors in the NSR group. The results showed that patients with high risk of SLNMs had worse prognosis than other NSR patients, and the survival differences were found in the subgroups pT3 and pT4a. This result is similar to that of patients with SLNMs who had worse survival in the CR group and SPR group (Fig. 1b-c, Fig. 2b-c) .
Next, the results indicated that patients with SLNMs who underwent No.10 and No.11 LN dissections and those who did not undergo these dissections but were at high risk of SLNM had similar prognosis. These results revealed that splenic hilar or splenic artery LN dissection did not improve survival for patients with SLNMs, whether or not splenectomy or spleen-preserving lymphadenectomy were performed. The poor prognosis of (Fig. 3) . However, in their study, no survival difference comparison was performed in patients with No.4 LN metastasis. Yang et al. [17] divided patients undergoing total gastrectomy for gastric cancer into two groups, with or without No.10 lymphadenectomy, and no statistically significant difference was found in the 5-year survival rate between the two groups. A limitation of Yang et al.'s study was that there was distributional bias of patients with No.10 LN metastasis in the two groups; for example, there was a greater percentage of patients with No.10 LN metastasis in the No.10 lymphadenectomy group. In our the study, we avoided this bias as well as The results demonstrated that the NSR group had a shorter operation time, lower incidence of perioperative transfusion, a shorter hospital stay, and lower incidence of non-lethal surgical complications.
This study should be interpreted in the context of its limitations. Although we excluded patients with direct tumor invasion of the spleen or pancreas, there was an unavoidable selection bias in the CR and SPR groups. Patients with more advanced tumors were selected to undergo CR, and patients who were highly suspected of having SLNM were selected to undergo SPR after the mid-1980s. Given the long time period and retrospective nature of this study, there were no standards to guide the lymphadenectomy approach chosen.
Conclusions
Our findings demonstrated that No.2/4 LN metastases and tumor invasion of the greater curvature were independent risk factors for No.10/11 LN metastases for APGC. Splenic hilar or splenic artery lymphadenectomy with splenectomy or spleen preservation was not associated with increased survival rate of patients with No.10/11 LN metastases. NSR: Nosplenic hilar orsplenic arteryLN resection;APGC: Advanced proximal gastric cancer a: one-way anova,b:χ2test; *:these patients had excluded from the study
